Kuboki, Y., Nakajima, T. E., Fujiwara, Y., Kitano, S., O’neil, B., Sommerhalder, D., … Yamamoto, N. (2025). Telisotuzumab adizutecan (Temab-A, ABBV-400), a novel c-Met antibody-drug conjugate, in Asian patients (pts) with advanced CRC: Results of a phase I study. In ANNALS OF ONCOLOGY (Vol. 36).

Kuboki, Y., T. E. Nakajima, Y. Fujiwara, S. Kitano, B. O’neil, D. Sommerhalder, M. R. Sharma, et al. “Telisotuzumab adizutecan (Temab-A, ABBV-400), a novel c-Met antibody-drug conjugate, in Asian patients (pts) with advanced CRC: Results of a phase I study.” In ANNALS OF ONCOLOGY, Vol. 36, 2025.

Kuboki Y, Nakajima TE, Fujiwara Y, Kitano S, O’neil B, Sommerhalder D, et al. Telisotuzumab adizutecan (Temab-A, ABBV-400), a novel c-Met antibody-drug conjugate, in Asian patients (pts) with advanced CRC: Results of a phase I study. In: ANNALS OF ONCOLOGY. 2025.

Kuboki, Y., et al. “Telisotuzumab adizutecan (Temab-A, ABBV-400), a novel c-Met antibody-drug conjugate, in Asian patients (pts) with advanced CRC: Results of a phase I study.” ANNALS OF ONCOLOGY, vol. 36, 2025.

Kuboki Y, Nakajima TE, Fujiwara Y, Kitano S, O’neil B, Sommerhalder D, Sharma MR, Powderly J, Strickler JH, Perets R, Cohen JE, Raimbourg J, Hunter Z, Quadri S, Blaney ME, Li RR, Vasilopoulos A, Abdelgawad I, Burns M, Yamamoto N. Telisotuzumab adizutecan (Temab-A, ABBV-400), a novel c-Met antibody-drug conjugate, in Asian patients (pts) with advanced CRC: Results of a phase I study. ANNALS OF ONCOLOGY. 2025.